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Short Communication
Enhancement of cytotoxicity of vindesine and cis-platinum
for human lung tumours by the use of verapamil in vitro
A.P. Simmondsl*, P. Moyes', A. Nicoll, K.G. Davidson2 & A. Faichney2
ICell Laboratory, Biochemistry and 2Cardiothoracic Surgical Unit, Royal Infirmary, Glasgow, UK.
The use of verapamil, a calcium channel antagonist,
to circumvent established resistance in human
cancer cell lines has been reported for lung
(Fetherston et al., 1985) and ovary (Rogan et al.,
1984) using adriamycin and the vinca alkaloids. We
were interested in its potential use for the
enhancement of cytotoxicity of vindesine and cis-
platinum in non-small cell cancer of lung (NSCCL).
An earlier study (Simmonds et al., 1986) using
primary patient material in clonogenic assay has
confirmed the overall poor clinical response rates to
these drugs reported by Elliott et al. (1984).
In this study, 18 lung tumour samples, 17
squamous and 1 adenocarcinoma, were removed at
thoracotomy of previously untreated patients and
grown in the bilayered agar clonogenic assay
system. In brief, samples were mechanically dis-
aggregated with crossed scalpels in Hanks
balanced salt solution (HBSS) with penicillin and
streptomycin and resulting cell suspensions passed
through needles of decreasing gauge to obtain single
cells. Tumour cells obtained were suspended in
RPM1-1640+10% FBS and aliquots of 106 viable
cells were exposed for 1 h at 37°C to concen-
trations representing 10% of the peak plasma
concentration for cis-platinum (0.25 pgml-1) and
vindesine (0.02pgml-1) (Alberts et al., 1980) with
and without verapamil and to verapamil alone
at 1 UM (450ngml- 1). Cells were washed with
HBSS+1% heat inactivated FBS and plated in
quadruplicate at 2 x 105 cells per plate in McCoy's
5A+10% FBS enriched with insulin (3 pml-1)
and 10nM hydrocortisone in 0.3% agar. Underlayers
consisted of the same medium plus 1% August
rat rbc in 0.5% agar. A day 0 plate was fixed in
glutaraldehyde/BSS for monitoring of any plated
clumps and the 3 plates remaining for each
treatment were incubated at 37°C in 5% C02/air
humidified atmosphere for 12 days.
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Plates were stained with INT violet at 37°C
overnight before colony scoring. Cultures were
examined with an inverted phase microscope at
x 100 and x 200 and aggregates of >32 cells were
counted as colonies. Where day 0 counts of fixed
plates exceeded 30, the assays were disregarded.
Counts less than these numbers were subtracted
from final counts and the plating efficiency (PE) of
each sample calculated from mean values of colony
counts for 3 plates. Replication between plates was
good, in our experience not exceeding 5%. Drug
results with and without verapamil were expressed
as mean percentage survival of colonies for each
treatment. Only samples with a minimum of 30
colonies in control plates (PE 0.015%) were
evaluated for drug sensitivity. These results were
deemed to be significant and samples were judged
sensitive if percentage survival was <50% of
control.
Figure 1 shows the response to cis-platinum. All
specimens except no. 13 were resistant in vitro when
tested alone, the degree of resistance varying from
moderate to very marked. Fourteen of the 18
patients demonstrated greater than 70% survival
following treatment with this drug. In the presence
of verapamil, only one patient, number 8, showed a
change to sensitivity from 60% to 36% survival.
Patient 13 had sensitivity changed to resistance
while samples number 7, 11, 12, 17 and 18
demonstrated increased resistance. A change in the
degree of resistance was observed for patients 2, 4,
5, 6, 9, 10, 14, and 15; this was lessened while
specimens from patients 1, 3 and 16 were
unaffected. Plating efficiencies in every case were
sufficiently high for these drug results to be
significant (11/18PE>0.03%) and the treatment of
cells with verapamil alone produced no cytotoxic
effects (figures not shown).
Figure 2 shows the response to vindesine. In the
absence of verapamil all samples were resistant and
10/18 patients exhibited greater than 70% survival
following treatment with this drug. Pronounced
changes, however, were observed in vindesine
response in the presence of verapamil for 7 samples;
patient numbers, 2, 5, 6, 7, 8 and 13 became
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Figure 1 Response of human lung tumours to cis-platinum (0.25jigml-1) in the presence and absence of
1 /im verapamil. (<50% survival =sensitivity).EM, + verapamil; El, verapamil.
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Figure 2 Response of human lung tumours to vindesine (0.02 igml 1) in the presense and absence of 1 UM
verapamil ( <50% survival =sensitivity). *, + verapamil; E], - verapamil.
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sensitive and patient number 14 had a marked
change in the degree of resistance. Four further
samples, 4, 15, 16 and 17 showed a lessening in the
degree of resistance while numbers 1, 3 and 9 were
unaffected and 10 and 18 demonstrated increased
resistance.
Analysis of the results for these 2 drugs with and
without verapamil shows clearly that verapamil
may have sensitizing effects to anti-cancer drugs
tested on fresh human lung tumour samples in
vitro. Effects are more marked with vindesine,
tumours treated with cis-platinum show little
sensitization to drug effects in this system. Thirty-
three per cent of patient samples tested had
vindesine response changed from resistant to
sensitive and it is reasonable to assume that such a
response might occur in vivo. The fact that these
effects were measured using clinically achievable
levels of verapamil, together with response at low
drug concentration as a basis for drug sensitivity in
vitro makes this more likely. Additionally
significant, however, is the fact that a further 28%
of samples had some response in favour of
increased sensitivity, while not falling into the
'sensitive' category in this test. Seventeen per cent
were unaffected and 11% showed an adverse
response. A difficulty in expressing the true
measure of verapamil effects arises from the fact
that sample size and number of evaluations
necessary to test any effect made it possible to test
only one concentration (10% peak plasma concen-
tration) for each drug. Although we are satisfied
that this value most closely resembles likely concen-
trations in vivo, changes in ID50 would be demon-
strated more clearly if dose response curves for a
range of drug concentrations could be constructed.
No relationship was observed between tumour
pathology and susceptibility to verapamil effects.
Patient number 8, the only one to show
sensitization to platinum in the presence of
verapamil, was a squamous carcinoma which
showed similar sensitization to vindesine. In
contrast, sample 13, also a squamous carcinoma,
which showed the greatest change in sensitivity to
vindesine, had sensitivity to platinum reversed to
resistance by a comparable degree. The adeno-
carcinoma, patient sample number 12, failed to
respond to verapamil in either drug combination.
The observation by other workers using cell lines
from a variety of malignancies, Merry et al. (1986)
for glioma, Tsuruo et al. (1983a) for Lewis lung,
B16 melanoma and 2 murine colon carcinomas,
Fetherston et al. (1985) for non-small cell cancer of
lung and Rogan et al. (1984) for cancer of ovary,
that in general the greater the resistance to drugs
under test, the greater the induced susceptibility
with verapamil, does not hold good in our study.
Mechanisms of enhancement of adriamycin and
vincristine responsiveness are largely due to
enhanced cellular accumulation by inhibition of
outward transport (Rogan et al. 1984; Tsuruo et
al., 1983a) and Tsuruo et al. (1983b) were able to
effect a 2-fold enhancement in adriamycin cyto-
toxicity using verapamil in human haematopoietic
cell lines. The poor cis-platinum response to
verapamil warrants further investigation as do the
pronounced effects recorded for vindesine. The
mechanism of apparent increased resistance for
some tumour samples in our system remains
unexplained. Some samples, e.g. 1 and 3, are
resistant to both drugs and remain so in the
presence of verapamil. This suggests that the
mechanisms of resistance may differ from tumour
to tumour within the same pathological sub-group.
For lung tumour cell lines, this has been suggested
already (Fetherston et al., 1985) but samples
studied in our system were primary samples from
previously untreated patients. Such resistance,
therefore, is inherent, rather than induced. We have
not had access to non small cell tumour specimens
in which resistance has been induced in vivo and are
therefore not in a position at this stage to compare
the effects of verapamil before and after treatment
with cytotoxic therapy on individual patients.
However, Cantwell et al. (1985) in a phase I and
subsequent phase II study using oral verapamil and
i.v. vindesine obtained clear responses in 1 squamous
and 1 adenocarcinoma of lung.
Our study demonstrating enhancement of
cytotoxic drug activity using clinical achievable
levels of verapamil, together with the success of a
pilot study in vivo, has encouraged the setting up of
a randomised clinical trial in small cell carcinoma
of lung (SCCL) by the West of Scotland Lung
Cancer Group (S.B. Kaye, personal communication).
We are grateful to Prof. S.B. Kaye, CRC Department of
Medical Oncology, Glasgow for helpful advice and
discussions.
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